Sanjin Pharmaceutical

Company Drug

China’s Guilin Sanjin Pharmaceutical Advances BC011 with NMPA Approval for Phase I Clinical Trial

Fineline Cube Aug 27, 2024

Guilin Sanjin Pharmaceutical Co. Ltd, a Chinese pharmaceutical company listed on the Shenzhen Stock Exchange...

Company Drug

Sanjin Pharma’s Subsidiary Gets NMPA Nod for BC007 Cancer Study

Fineline Cube Aug 17, 2022

China-based Guilin Sanjin Pharmaceutical Co. Ltd (SHE: 002275) announced that its subsidiary, Dragon Boat Biopharmaceutical...

Company Drug

Sanjin Pharma’s Subsidiary Gets FDA Nod for BC007 Cancer Drug Trial

Fineline Cube Aug 1, 2022

China-based Guilin Sanjin Pharmaceutical Co. Ltd (SHE: 002275) announced that its subsidiary, Dragon Boat Pharmaceutical...

Company Deals

Johnson & Johnson Completes Acquisition of Intra-Cellular Therapies

Company Deals Medical Device

Yuewei Medtech Secures RMB100 Million in Series A++ Funding for Cardiac Device Development

Company

Boehringer Ingelheim Reports 6.1% Sales Growth in 2024, Bolstered by Key Pharmaceuticals

Company Deals

GE Healthcare Partners with Probo Medical to Distribute Ultrasound Devices